News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Visiox Pharmaceuticals, Inc. Announces Landmark Merger with Ocuvex Therapeutics, Inc.

Tuesday, August 20, 2024

Visiox Pharmaceuticals Inc has announced a definitive merger agreement with Ocuvex Therapeutics Inc a privately held ophthalmic pharmaceutical company dedicated to developing and commercializing innovative therapies for glaucoma and other eye disorde...

TEPKINLY® (epcoritamab) Secures Second European Commission Approval for Treating Adults with Relapsed/Refractory Follicular Lymphoma

Tuesday, August 20, 2024

Genmab AS announced that the European Commission EC has granted conditional marketing authorization for TEPKINLY epcoritamab as a monotherapy for the treatment of adult patients with relapsed or refractory RR follicular lymphoma FL after two or more...

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Monday, August 19, 2024

Clearmind Medicine Inc a biotech company dedicated to the discovery and development of innovative psychedelicderived therapeutics for addressing significant unmet health needs announced today the submission of a patent application under the internati...

SciSparc Finalizes $3 Million Exclusive Global Out-Licensing Agreement for Its Pain Therapy

Monday, August 19, 2024

SciSparc Ltd a specialty clinicalstage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases announced the signing of an Exclusive Patent License Agreement with Polyrizon Ltd Polyrizon This agre...

Silo Pharma Expands Collaboration with Sever Pharma for Novel Ketamine Implant Therapeutic

Friday, August 16, 2024

Silo Pharma Inc a developmentalstage biopharmaceutical company specializing in novel drug formulations and delivery systems for traditional and psychedelic therapies today announced a new agreement with Sever Pharma Solutions This collaboration focus...

Certara Launches Phoenix™ Version 8.5 Drug Development Software

Friday, August 16, 2024

Certara Inc a global leader in modelinformed drug development today announced the launch of Phoenix version Phoenix is the pharmaceutical industrys gold standard in pharmacokinetic pharmacodynamic PKPD and toxicokinetic modeling and simulation soft...

Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine

Wednesday, August 14, 2024

Bavarian Nordic AS announced that the US Food and Drug Administration FDA has accepted and granted Priority Review for the Biologics License Application BLA for CHIKV VLP the Companys vaccine candidate for immunization to prevent disease caused

Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment

Wednesday, August 14, 2024

Insignis Therapeutics a pharmaceutical company focused on developing innovative allergy and anaphylaxis treatments is pleased to announce that the US Food and Drug Administration FDA has granted Fast Track designation for its investigational drug IN...

Blue Earth Therapeutics Ltd Expands Partnership with Seibersdorf Labor GmbH to Include Manufacturing of Therapeutic Radiopharmaceutical 225Ac-rhPSMA-10.1

Tuesday, August 13, 2024

Blue Earth Therapeutics Ltd a Bracco company and a rising leader in innovative nextgeneration therapeutic radiopharmaceuticals has announced the expansion of its manufacturing agreements with Seibersdorf Labor GmbH This partnership now includes the p...

Persist AI and Nivagen Announce Collaboration on AI-Driven Manufacturing Process for Long-Acting Injectables

Tuesday, August 13, 2024

Persist AI and Nivagen have announced a collaboration to codevelop a nextgeneration manufacturing process for longacting injectable LAI drugs using Persists AIbased formulation technology and Nivagens manufacturing capabilities The collaboration aims...